Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. (NASDAQ: ILMN) today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. (IBS) and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware. In its counterclaims, Illumina has sued IBS and Qiagen for infringement of three Illumina patents, entitled "Labelled Nucleotides." These three patents (U.S. Patent Nos. 7,057,026; 7,785,796; and 8,158,346, all expiring in December 2022), are applicable to the sequencing by synthesis technology being used in the IBS Max-Seq and MINI-20 DNA Sequencers. Illumina is seeking all available remedies, including injunctive relief. With respect to the claims brought by Columbia and IBS, Illumina has denied all of Columbia's and IBS's allegations of patent infringement, and has asserted that Columbia's patents are invalid.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S., and many additional patents granted worldwide, to protect its massive investments in research and development and resulting technological breakthroughs.

"As we have said in the past, Illumina strongly prefers to compete in the marketplace. However, we are determined to use our IP to protect our market position, acquired through Illumina's history of unmatched innovation, so that our customers can continue to benefit from resulting technological advances that are changing the economics of genetic research," said Jay Flatley, President and CEO of Illumina.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2019, June 20). Illumina sues IBS and Qiagen for infringement of three patents. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20120723/Illumina-sues-IBS-and-Qiagen-for-infringement-of-three-patents.aspx.

  • MLA

    Illumina, Inc.. "Illumina sues IBS and Qiagen for infringement of three patents". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20120723/Illumina-sues-IBS-and-Qiagen-for-infringement-of-three-patents.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina sues IBS and Qiagen for infringement of three patents". News-Medical. https://www.news-medical.net/news/20120723/Illumina-sues-IBS-and-Qiagen-for-infringement-of-three-patents.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2019. Illumina sues IBS and Qiagen for infringement of three patents. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20120723/Illumina-sues-IBS-and-Qiagen-for-infringement-of-three-patents.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert